Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Milestone Pharmaceuticals Inc. filings document a commercial-stage biopharmaceutical company focused on cardiovascular medicines, including CARDAMYST (etripamil) nasal spray for adults with PSVT. Its 8-K filings report financial results, commercial launch updates, regulatory and corporate updates, Regulation FD presentations and material events related to etripamil.
The filing record also covers Milestone's Nasdaq-listed common shares, proxy governance for annual shareholder meetings, board and voting matters, and capital-structure items such as the completed sale of a royalty interest tied to U.S. etripamil net product sales. These disclosures provide formal records of operating results, governance, financing arrangements and product-related corporate events.
RTW Investments and Roderick Wong reported beneficial ownership of 12,356,953 common shares of Milestone Pharmaceuticals, representing 9.99% of the class. The cover pages assume exercise of warrants to purchase 6,025,952 shares subject to a 9.99% beneficial ownership cap.
The filing bases percentages on 117,667,277 shares outstanding as of March 20, 2026. The Reporting Persons state shared voting and dispositive power over the 12,356,953 shares. The statement is an amended Schedule 13G/A signed on May 15, 2026.
Milestone Pharmaceuticals Inc. filed a shelf registration on to offer up to $300,000,000 of common shares, preferred shares, debt securities and/or warrants. The filing includes a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. for up to $100,000,000 of common shares to be sold from time to time.
The prospectus states the base shelf covers multiple issuance methods and that specific terms, pricing and offering mechanics will be provided in prospectus supplements. Cash‑flow treatment and timing are tied to future prospectus supplements and the sales agreement; the company lists general corporate uses for proceeds.
Milestone Pharmaceuticals Inc. reporting persons led by Adage Capital Management, L.P. state beneficial ownership of 8,000,000 shares, representing 6.37% of the class, issuable upon exercise of warrants. The percentage is calculated using 117,667,277 Common Shares outstanding as of March 20, 2026.
The filing identifies the reporting persons and their shared voting and dispositive power with respect to the warrants and notes the address and CUSIP 59935V107.
Milestone Pharmaceuticals reported first quarter 2026 results and its first commercial sales of CARDAMYST for paroxysmal supraventricular tachycardia. Product revenue, net was $238 thousand, reflecting the early launch, while the company recorded a net loss of $26,066 thousand, or $0.20 per share, compared with a net loss of $20,761 thousand a year earlier.
Commercial expenses rose as the company invested $15,812 thousand in launch activities, up from $10,378 thousand in 2025. As of March 31, 2026, Milestone held cash and cash equivalents of $71,317 thousand and short-term investments of $112,899 thousand. Management highlighted positive early prescriber adoption, Express Scripts national formulary coverage for CARDAMYST, and initiation of a Phase 3 pivotal trial of etripamil in atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals reported its first quarter of commercial sales for CARDAMYST, its newly approved nasal spray for paroxysmal supraventricular tachycardia, generating $0.2 million in product revenue for the three months ended March 31, 2026. The company remains in an investment phase, with a net loss of $26.1 million compared with $20.8 million a year earlier, driven mainly by higher commercial spending.
Milestone ended the quarter with cash, cash equivalents and short-term investments of $184.2 million, and believes this balance will fund planned operations for at least 12 months. During the quarter it received $75 million from a royalty financing tied to future U.S. CARDAMYST sales and raised additional equity via an at-the-market program and warrant exercises, while continuing development of etripamil for atrial fibrillation with rapid ventricular rate.
Milestone Pharmaceuticals Inc. is asking shareholders to vote at a virtual-only 2026 Annual Meeting on June 10, 2026 at 11:00 a.m. Eastern Time. Shareholders of record as of April 15, 2026, when 119,637,391 common shares were outstanding, may vote online, by phone or by mail.
Investors will elect eight directors, ratify PricewaterhouseCoopers LLP as auditor through the 2027 meeting, approve an increase of 6,800,000 shares under the 2019 Equity Incentive Plan, and cast a non-binding advisory vote on executive compensation. The Board, led by an independent chair, recommends voting FOR all proposals and highlights strong governance practices, including a majority-independent board, fully independent key committees and no shareholder rights plan.
Milestone Pharmaceuticals President and CEO Joseph Oliveto sold 36,500 common shares of the company in an open-market transaction on April 16, 2026 at a weighted average price of $2.26 per share. The shares were sold in multiple trades between $2.25 and $2.28 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan previously adopted by Oliveto, meaning the trades were pre-scheduled rather than discretionary. Following this transaction, he continues to hold 446,244 common shares directly.